000990 Chengzhi Co.,Ltd.
- 8.79
- +0.22+2.57%
Chengzhi Co.,Ltd. News
The synthetic biology concept opened low and went up and down, and Sanyuan Biotech, Fuxiang Pharmaceutical, Meibang Technology, Chengzhi Co., Ltd., and Walter Co., Ltd. followed suit.
The synthetic biology concept opened low and went up and down, and Sanyuan Biotech, Fuxiang Pharmaceutical, Meibang Technology, Chengzhi Co., Ltd., and Walter Co., Ltd. followed suit.
Express News | Chengzhi Co., Ltd.: The company does not produce artificial meat. The company's product D-ribose is purchased by some artificial meat manufacturers as a raw material for the production of artificial meat
Chengzhi Co., Ltd. (000990.SZ): D-ribose can be used as a starting ingredient for certain COVID-19 drugs
Gelonghui May 13 丨 Some investors asked Chengzhi Co., Ltd. (000990.SZ) on the investor interactive platform, “Can the company's products be used for COVID-19 drugs?” The company replied that the company's D-ribose can be used as a starting ingredient for certain COVID-19 drugs.
Chengzhi Co., Ltd. (000990.SZ): The synthetic biology business is one of the company's main businesses in the biomedical sector
Gelonghui, May 9 | Chengzhi Co., Ltd. (000990.SZ) said on the investor interactive platform that the synthetic biology business is one of the company's main businesses in the biomedical sector. Among them, production and sales of the company's D-ribose series products have grown rapidly in recent years. Currently, they dominate the global market and are widely used in medicine, nutrition and health care, food and beverage, clinical nutrition, etc. D-mannose developed by the company was mass-produced in 2023, and product sales have been growing steadily.
Chengzhi Co., Ltd. (000990.SZ): A new enzyme independently developed using synthetic biology technology has completed strain construction and the development of a new process for enzyme conversion, and is currently undergoing testing
Gelonghui, May 9 | Chengzhi Co., Ltd. (000990.SZ) said on the investor interactive platform that the company has independently developed a new enzyme using synthetic biology technology that has completed strain construction and the development of a new process for enzyme conversion. It is currently undergoing testing and certification, and has applied for a number of patents. In 2023, the company cooperated with Academician Tan Tianwei's team to establish the “Chengzhi Co., Ltd. - Beijing University of Chemical Technology Joint Engineering Research and Transformation Center” to carry out in-depth cooperation in strain construction and enzyme modification, process optimization and technology iteration, incubation of innovative achievements, etc., to continuously enrich product categories and promote the company's high-quality development. The future, the company
Express News | Chengzhi Co., Ltd.: In the field of synthetic biology, there are mainly products such as D-ribose, and other products are being prepared
Express News | Chengzhi Co., Ltd.: Currently, the company's products in the field of synthetic biology mainly include D-ribose sugar, D-mannose, etc.
Express News | Chengzhi Co., Ltd. cooperated with Academician Tan Tianwei's team to establish a synthetic biology joint engineering research and transformation center
Chengzhi Co., Ltd. (000990.SZ): Overseas business is mainly TFT LCD products, D-ribose and other products
Gelonghui, April 18, 丨 Chengzhi Co., Ltd. (000990.SZ) held a performance briefing on April 17, 2024. Regarding “Can you talk about the development of the company's overseas business, the intensification of domestic competition, and whether overseas business expansion will increase”, the company replied that the company's overseas business is mainly products such as TFT LCD products and D-ribose, and the market sales of these products are good. In the future, dynamic adjustments will be made according to domestic and foreign market conditions.
Express News | Fourteen listed companies disclosed their 2024 quarterly reports, with three squirrels leading the way in revenue of 3.646 billion yuan
Chengzhi Co., Ltd. (000990.SZ) announced first-quarter results, net profit of 154 million yuan, reversing year-on-year losses
Chengzhi Co., Ltd. (000990.SZ) released its report for the first quarter of 2024, achieving operating income of 27 during the reporting period...
Chengzhi Co., Ltd. (000990.SZ): POE downstream consumption structure includes TPO terminals, polymer modifications, wires and cables, etc.
Gelonghui, April 11 | Chengzhi Co., Ltd. (000990.SZ) said on the investor interactive platform that the POE downstream consumption structure includes TPO terminals, polymer modifications, wires and cables, etc.
Chengzhi Acquires Liquid Crystal Material Patent From DIC for 4.97 Billion Yen
Chengzhi (SHE:000990) agreed to acquire 1,183 liquid crystal material patent from Japan's DIC for 4.97 billion Japanese yen, according to the company's disclosure on the Shenzhen Stock Exchange. The p
Express News | Chengzhi Co., Ltd.: The subsidiary plans to purchase 1,183 patent assets for 4,967 billion yen
Chengzhi Co., Ltd. (000990.SZ): Chengzhi Innovation plans to participate in the subscription for a fund share of 100 million yuan from Qingdao Chuxin
On March 21, Ge Longhui Co., Ltd. (000990.SZ) announced that the company's wholly-owned subsidiary, Beijing Chengzhi Technology Innovation Development Co., Ltd. (“Chengzhi Innovation”), plans to subscribe for a fund share of 100 million yuan from Qingdao Chuxin Haiping Equity Investment Fund Partnership (Limited Partnership) (“Qingdao Chuxin” or “Fund” for short) in order to continuously improve profitability and accelerate its layout in the semiconductor field. Qingdao Chuxin is a limited partnership established in accordance with law. The fund size is 1 billion yuan. The fund is managed by Qingdao Xinping Investment Management Co., Ltd. (“Qingdao Xinping” for short). The main investors in the fund
Chengzhi Co., Ltd. (000990.SZ): The subsidiary Nanjing Chengzhi produces hydrogen mainly for use by surrounding supporting companies
Gelonghui March 13 丨 Some investors asked Chengzhi Co., Ltd. (000990.SZ) on the investor interactive platform, “What are your company's main hydrogen sales areas?” The company replied that the hydrogen produced by its subsidiary Nanjing Chengzhi is mainly used by surrounding supporting companies, and that surplus hydrogen will be used for the operation and use of hydrogen refueling stations.
Chengzhi Co., Ltd. (000990.SZ): 2023 net profit of 177 million yuan increased 248.36% year-on-year
On March 12, Ge Longhui Co., Ltd. (000990.SZ) released its 2023 annual report. Operating income was 12.417 billion yuan, up 5.97% year on year, net profit of 177 million yuan, up 248.36% year on year, after deducting non-net profit of 152 million yuan, up 671.90% year on year, with basic earnings per share of 0.1,460 yuan.
Chengzhi Co., Ltd. (000990.SZ): The subsidiary plans to participate in the establishment of Qingdao Dingrong Xinxing Private Equity Fund
Gelonghui, March 12, 丨 Chengzhi Co., Ltd. (000990.SZ) announced that its wholly-owned subsidiary Beijing Chengzhi Technology Innovation Development Co., Ltd. intends to participate as a limited partner in the establishment of the Qingdao Dingrong Xinxing Private Equity Investment Fund Partnership (limited partnership) (“Dingrong Emerging Fund”). The total target size of Dingrong Emerging Fund is no more than 700 million yuan, and the initial scale is no more than 230 million yuan. The limited partners entered in batches during the fundraising period and completed pledges of the corresponding scale. As a limited partner, Chengzhi Innovation plans to pledge an investment of RMB 98 million, accounting for no less than 14.00% of the total scale mentioned above. Among them, the first
Chengzhi Co., Ltd. (000990.SZ): The main products are nutritional supplement products such as D-ribose, libose, probiotics, etc.
On March 7, Ge Longhui Co., Ltd. (000990.SZ) said on the investor interactive platform that in the biomedical field, as the only company in the world with complete intellectual property rights for D-ribose, the company has actively invested in development for more than 20 years. Its main products are nutritional supplement products such as D-ribose, Levos, and probiotics. The company will continue to explore the D-ribose market, increase its market share, accelerate the construction of multi-purpose workshops and API workshop projects, further expand the diversification of product structures, keep up with cutting-edge synthetic biology research, focus on the big health industry, and deepen the large-scale development of the company's bio-manufacturing materials sector.
A-share midday announcement: Haozhi Mechatronics received 5.7047 million yuan in government subsidy
Gelonghui, February 2 | ① Haozhi Electromechanical: The company and its subsidiary Yueyang Xianlong Motor Co., Ltd. received a total of 5.7047 million yuan in government subsidies from December 12, 2023 to January 31, 2024. ② Andawel: Beijing Andawel Aviation Equipment Co., Ltd., a wholly-owned subsidiary, received 5.276,000 yuan in government grants from the Beijing Haidian District Taxation Bureau on February 1, accounting for 11.52% of the absolute value of the company's latest net profit. ③ Sinochem Geotechnical: From the company's disclosure of the “Notice on Progress in Litigation and Arbitration Matters” on September 22, 2023 to the disclosure date of this announcement, except
Analysis
Price Target
No Data
